首页> 外文期刊>Coronary artery disease >Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
【24h】

Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

机译:炎症和冠状动脉疾病:从病理生理学到Canakinumab抗炎血栓形成结果研究(Cantos)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The worldwide prevalence of cardiovascular disease in general and atherosclerotic coronary artery disease in particular is a health and economic concern of unparalleled proportion. Despite a long history of astute observations beginning in 1575 made by Fallopius, followed by those of von Rokatansky, Virchow, Osler, and Ross, and incremental knowledge of the pathobiology of atherosclerosis to include varying stages of inflammation, response to internally and externally mediated vascular injury, and impaired homeostasis, gaps in the field's understanding persist. Here, we summarize the current scope of the problem for coronary artery disease, emerging constructs in its pathobiology and common clinical phenotypes, potentially useful biomarkers, clinical trials designed specifically to test the inflammation hypothesis' of disease, and the interface of pathobiology and precision medicine as a foundation for diagnosis, management, and future advances in the diagnosis, prognosis, natural history, prevention, and optimal management.
机译:特别是全球心血管疾病的患病率和动脉粥样硬化冠状动脉疾病是一种无与伦比的比例的健康和经济问题。尽管历史悠久的精明观察历史,但从秋季毕马制作的1575年开始,其次是冯·洛克本体,生命,蒸发物和罗斯的历史,以及动脉粥样硬化病病病病病病病病病毒学的增量知识,包括不同炎症的不同阶段,对内部和外部介导的血管反应损伤和障碍受损,领域的理解态度持续存在。在这里,我们总结了冠状动脉疾病问题的当前范围,其病病毒学和常见的临床表型,潜在的有用生物标志物,专门设计疾病炎症假设的临床试验,以及病原体学和精密药物的界面作为诊断,管理和未来进展的基础,预后,自然历史,预防和最佳管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号